Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cbiz (CBZ) Shares Outstanding (Diluted Average) (2018 - 2025)

Cbiz's Shares Outstanding (Diluted Average) history spans 11 years, with the latest figure at $63.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 20.09% year-over-year to $63.2 million; the TTM value through Dec 2025 reached $63.2 million, up 20.09%, while the annual FY2025 figure was $63.2 million, 20.09% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $63.2 million in Q4 2025 per CBZ's latest filing, down from $63.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $64.1 million in Q1 2025 to a low of $50.2 million in Q1 2024.
  • Average Shares Outstanding (Diluted Average) over 5 years is $54.4 million, with a median of $52.7 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): decreased 4.14% in 2023, then increased 27.72% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $53.7 million in 2021, then decreased by 2.48% to $52.4 million in 2022, then dropped by 3.5% to $50.6 million in 2023, then rose by 4.16% to $52.7 million in 2024, then rose by 20.09% to $63.2 million in 2025.
  • Per Business Quant, the three most recent readings for CBZ's Shares Outstanding (Diluted Average) are $63.2 million (Q4 2025), $63.6 million (Q3 2025), and $64.0 million (Q2 2025).